Heart Failure Clinical Trials in New Haven, Connecticut

10 studies are recruiting for heart failure in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

   Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05753059 on ClinicalTrials.gov

2. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Yale New Haven Health Heart & Vascular Center Outpatient Services, New Haven, Connecticut

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

3. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, New Haven, Connecticut

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

4. Promoting Palliative Care for People With Heart Failure

   This project will develop and test a novel clinical decision support tool (CDS) that encourages timely referral to palliative care for people hospitalized with heart failure. This intervention will incorporate an existing, validated 1-year mortality risk model into a CDS to deliver prognostic infor…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Yale New Haven Hospital Saint Raphael, New Haven, Connecticut

   Locations

   2 in total

   Run by

   Yale University

   See if you can join NCT06933875 on ClinicalTrials.gov

5. Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

   This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05323487 on ClinicalTrials.gov

6. Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

   Randomized double-blind placebo-controlled crossover study design

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06209359 on ClinicalTrials.gov

7. Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

   The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mor…

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Yale New Haven Hospital-St. Raphael Campus, New Haven, Connecticut

   Locations

   2 in total

   Run by

   Yale University

   See if you can join NCT07273838 on ClinicalTrials.gov

8. Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

   The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Yale New Haven Health System, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT04237701 on ClinicalTrials.gov

9. Ertugliflozin in Chronic Heart Failure

   The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this st…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale School of Medicine, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT04438213 on ClinicalTrials.gov

10. Left vs Left Randomized Clinical Trial

    The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications an…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Locations

    71 in total

    Run by

    Baylor College of Medicine

    See if you can join NCT05650658 on ClinicalTrials.gov